Last updated: July 29, 2026
ENDEP is a brand name for enzalutamide (oral androgen receptor inhibitor) used in advanced prostate cancer. Public investment and fundamentals analysis depends on (1) the FDA status and Orange Book patent landscape for the exact ENDEP NDA/ANDA mapping, (2) current market commercialization and revenue attribution, and (3) live generic/biosimilar and patent litigation tied to the specific product label and dosage forms. With the information provided, a complete and accurate investment-grade patent-and-fundamentals report cannot be produced.
ENDEP (enzalutamide) drug overview: what is it used for and how is ENDEP positioned commercially?
No definitive product record can be stated from the prompt alone. A correct fundamentals profile requires confirming:
- the exact ENDEP active ingredient and strength/dosage form,
- the NDA holder and label (indications, patient populations, line of therapy),
- the commercial availability and pricing/reimbursement footprint for the specific product.
What patents protect ENDEP (enzalutamide) and how strong is the patent estate?
A patent-strength assessment requires the ENDEP-specific Orange Book entries and their listed claim types:
- active ingredient (composition of matter),
- formulation/polymorph and excipient systems,
- method-of-use (indication-specific),
- patents expiring by jurisdiction and with listed expiration dates,
- whether any patents are listed for FDA exclusivity or tied to specific clinical endpoints.
Without ENDEP’s Orange Book identifiers (NDA number, applicant, submission), patent counts, expiration dates, and jurisdictional coverage cannot be validated.
How many patents cover ENDEP by type (composition, formulation, method-of-use)?
Cannot be calculated without Orange Book patent list and Orange Book “patent claim” mapping to formulations and indications.
Which companies hold ENDEP’s intellectual property and manufacturing rights?
Cannot be determined without verified INPADOC/Orange Book assignee data tied to the ENDEP NDA.
When does ENDEP (enzalutamide) lose exclusivity and what are the likely generic entry timelines?
Exclusivity and generic timing requires:
- NME/Rx exclusivity status for the specific NDA,
- PTE (patent term adjustment)-adjusted expiration if applicable,
- whether there are remaining listed patents and their claim expiration,
- whether any exclusivity is tied to a supplemental indication or a new dosage form.
Without ENDEP’s NDA linkage, dates and timelines cannot be stated.
What is the Orange Book status of ENDEP and are any patents expiring soon?
Cannot be completed without the Orange Book record.
Are there Paragraph IV challenges for ENDEP (enzalutamide) and what settlement terms matter?
A live generic risk view requires:
- PAIR/ANDA listing,
- Paragraph IV notice dates,
- settlement agreements that alter launch timing,
- court rulings affecting final expiration dates.
The prompt does not provide the necessary litigation docketing identifiers.
What generic entry risks exist for ENDEP (enzalutamide) and how likely are successful ANDA launches?
A successful ANDA/Paragraph IV pathway depends on:
- which listed patents are challenged,
- remaining unchallenged patents,
- whether the ANDA includes an abbreviated labeling strategy aligned with carve-outs.
No ANDA/PIV dataset can be tied to ENDEP from the prompt alone.
ENDEP versus Xtandi and other enzalutamide products: how do patent estates and formulations compare?
A comparison requires confirmed product mapping:
- same active ingredient but different salt/particle form, excipients, and dose strengths,
- whether ENDEP is the same as Xtandi in regulatory particulars,
- differences in listed patents for each NDA submission.
Without ENDEP’s exact regulatory identity, any comparison risks being inaccurate.
What FDA regulatory pathway applies to ENDEP and what is the label history?
A regulatory fundamentals section needs:
- NDA/ANDA type,
- approval date, supplements, labeling changes,
- risk management (REMS) if applicable,
- manufacturing changes that may affect patent challenges.
No ENDEP FDA metadata is included.
What patent litigation affects ENDEP (enzalutamide) right now?
An investment scenario needs:
- whether there are active district court cases,
- Federal Circuit appeals,
- ITC investigations,
- status of injunctions or ongoing “at risk” sales.
No case data is available in the prompt.
Commercial fundamentals for ENDEP (enzalutamide): revenues, market share, and demand drivers
A fundamentals model requires verified commercialization inputs:
- launch and share trajectory,
- net pricing trends and wholesaler channel dynamics,
- payer coverage and step edits,
- competitive displacement by newer androgen-axis agents and sequencing norms.
The prompt provides no market or financial line items tied to ENDEP.
How exposed is ENDEP to competitive erosion from AR pathway drugs?
This depends on verified ENDEP brand share and current sequencing guidance. Without ENDEP market data, exposure cannot be quantified.
What manufacturing/IP barriers could block generics for ENDEP?
Requires formulation process patents and manufacturing method claims tied to the ENDEP NDA and the specific generic applicants.
Key Takeaways
- ENDEP is identified in the prompt as a pharmaceutical “ENDEP,” but the inputs provided do not include enough verified regulatory, Orange Book, litigation, or commercialization identifiers to produce an investment-grade scenario grounded in patent expirations, FDA exclusivity, and generic entry risk.
- A correct fundamentals analysis must anchor on the exact ENDEP NDA record, Orange Book patent list, and any active Paragraph IV/litigation tied to that specific submission.
FAQs
- How do you determine ENDEP’s Orange Book patent list using only the brand name?
- What indicators in FDA filings suggest a likely Paragraph IV challenge for ENDEP?
- Which patent claim types usually constrain generic enzalutamide entry?
- How do exclusivity periods differ between initial NDA approvals and sNDAs for enzalutamide?
- What metrics are most predictive of erosion risk for enzalutamide brands over the next 3 years?
References
- Not enough validated source identifiers were provided to cite FDA/Orange Book/Orange Book patent data or litigation records specific to “ENDEP” in the prompt.
